SCHEMBL3033282

SCHEMBL3033282

CCCCCCCCC(=O)CCCCCCC(=O)OC

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.59
KMT2A Q03164 1/20 0.59
TSHR P16473 3/20 0.58
DGKA P23743 1/20 0.57
POLB P06746 1/20 0.56
POLA1 P09884 1/20 0.56
LMNA P02545 3/20 0.53
HAO1 Q9UJM8 1/20 0.53
CA12 O43570 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
PAM P19021 2/20 0.52
ALDH1A1 P00352 1/20 0.52
EPHX2 P34913 1/20 0.51
CES2 O00748 3/20 0.50
CES1 P23141 3/20 0.50
KDM5A P29375 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31190487 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL12192678 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL6415465 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL16046101 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL20637044 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL40101 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL7112187 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL3621835 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL19816815 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB
SCHEMBL15689621 1.00 MAPT (0.59) MAPTKMT2ATSHRDGKAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10478464-B2 Compositions and methods of use Shah, Kirit (US) 2019-11-19 US disclosed
EP-2381950-B1 hydroxyhexadecanoic acid for the treatment of cancer VANAS ONCOLOGY (US) 2013-11-13 EP disclosed
EP-2381950-B1 hydroxyhexadecanoic acid for the treatment of cancer VANAS ONCOLOGY (US) 2013-11-13 EP disclosed
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-08-19 US disclosed
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-08-19 US disclosed
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-08-19 US disclosed
WO-2010083311-A2 COMPOSITIONS AND METHODS OF USE VANAS ONCOLOGY (US) 2010-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100209543-A1 COMPOSITIONS AND METHODS OF USE MKI67, VHL, CCNC MAPT 616/4885KMT2A 2157/4885TSHR 4443/4885
US-10478464-B2 Compositions and methods of use MKI67, VHL, CCNC MAPT 616/4885KMT2A 2157/4885TSHR 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.